BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 95.85 USD -1.47% Market Closed
Market Cap: 23B USD

BioNTech SE
Other Operating Expenses

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BioNTech SE
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
BioNTech SE
NASDAQ:BNTX
Other Operating Expenses
-€641.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Other Operating Expenses
-€24.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Other Operating Expenses
€94k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Other Operating Expenses
€7.1m
CAGR 3-Years
10%
CAGR 5-Years
-3%
CAGR 10-Years
19%
Heidelberg Pharma AG
XETRA:HPHA
Other Operating Expenses
-€339.1k
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Other Operating Expenses
-€487k
CAGR 3-Years
N/A
CAGR 5-Years
34%
CAGR 10-Years
13%
No Stocks Found

BioNTech SE
Glance View

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
54.88 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is BioNTech SE's Other Operating Expenses?
Other Operating Expenses
-641.2m EUR

Based on the financial report for Dec 31, 2024, BioNTech SE's Other Operating Expenses amounts to -641.2m EUR.

Back to Top